These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 37080859)
1. [Biological, preclinical and clinical aspects of the association between radiation therapy and CDK4/6 inhibitors]. Beddok A; Porte B; Cottu P; Fourquet A; Kirova Y Cancer Radiother; 2023 May; 27(3):240-248. PubMed ID: 37080859 [TBL] [Abstract][Full Text] [Related]
2. Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer. Visani L; Livi L; Ratosa I; Orazem M; Ribnikar D; Saieva C; Becherini C; Salvestrini V; Scoccimarro E; Valzano M; Cerbai C; Desideri I; Bernini M; Orzalesi L; Nori J; Bianchi S; Morandi A; Meattini I Radiother Oncol; 2022 Dec; 177():40-45. PubMed ID: 36349599 [TBL] [Abstract][Full Text] [Related]
3. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer. Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562 [TBL] [Abstract][Full Text] [Related]
4. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer. Sobhani N; D'Angelo A; Pittacolo M; Roviello G; Miccoli A; Corona SP; Bernocchi O; Generali D; Otto T Cells; 2019 Apr; 8(4):. PubMed ID: 30959874 [TBL] [Abstract][Full Text] [Related]
5. Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers. Pesch AM; Hirsh NH; Chandler BC; Michmerhuizen AR; Ritter CL; Androsiglio MP; Wilder-Romans K; Liu M; Gersch CL; Larios JM; Pierce LJ; Rae JM; Speers CW Clin Cancer Res; 2020 Dec; 26(24):6568-6580. PubMed ID: 32967938 [TBL] [Abstract][Full Text] [Related]
6. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934 [TBL] [Abstract][Full Text] [Related]
7. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update. O'Sullivan CC Expert Opin Pharmacother; 2016 Aug; 17(12):1657-67. PubMed ID: 27322766 [TBL] [Abstract][Full Text] [Related]
8. Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis. Becherini C; Visani L; Caini S; Bhattacharya IS; Kirby AM; Nader Marta G; Morgan G; Salvestrini V; Coles CE; Cortes J; Curigliano G; de Azambuja E; Harbeck N; Isacke CM; Kaidar-Person O; Marangoni E; Offersen B; Rugo HS; Morandi A; Lambertini M; Poortmans P; Livi L; Meattini I Cancer Treat Rev; 2023 Sep; 119():102586. PubMed ID: 37336117 [TBL] [Abstract][Full Text] [Related]
9. Impact of cyclin dependent kinase 4/6 inhibitors on breast cancer brain metastasis outcomes. Chew SM; Ferraro E; Safonov A; Chen Y; Kelly D; Razavi P; Robson M; Seidman AD Eur J Cancer; 2024 Aug; 207():114175. PubMed ID: 38896996 [TBL] [Abstract][Full Text] [Related]
10. Outcomes and toxicity of concurrent CDK4/6 inhibitor and locoregional radiotherapy for patients with de novo metastatic breast cancer. Beddok A; Mouren V; Cottu P; Laki F; Fourquet A; Kirova Y Int J Cancer; 2023 Oct; 153(7):1386-1396. PubMed ID: 37381597 [TBL] [Abstract][Full Text] [Related]
11. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors. Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484 [TBL] [Abstract][Full Text] [Related]
12. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells. Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163 [TBL] [Abstract][Full Text] [Related]
13. Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data. Martin JM; Handorf EA; Montero AJ; Goldstein LJ Oncologist; 2022 Jun; 27(6):441-446. PubMed ID: 35552450 [TBL] [Abstract][Full Text] [Related]
14. Incidence of and risk factors for non-hematologic toxicity with combined radiotherapy and CDK4/6 inhibitors in metastatic breast cancer using dose-volume parameters analysis: a multicenter cohort study. Kawamoto T; Shikama N; Imano N; Kubota H; Kosugi T; Sekii S; Harada H; Yamada K; Naoi Y; Miyazawa K; Hirano Y; Wada Y; Tonari A; Saito T; Uchida N; Araki N; Nakamura N Breast Cancer; 2023 Mar; 30(2):282-292. PubMed ID: 36528759 [TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies. Kwapisz D Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711 [TBL] [Abstract][Full Text] [Related]
16. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. Spring LM; Zangardi ML; Moy B; Bardia A Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010 [TBL] [Abstract][Full Text] [Related]
17. Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis. Kubeczko M; Jarząb M; Gabryś D; Krzywon A; Cortez AJ; Xu AJ Radiother Oncol; 2023 Oct; 187():109839. PubMed ID: 37536378 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Kim SB Cancer Res Treat; 2022 Apr; 54(2):469-477. PubMed ID: 34176251 [TBL] [Abstract][Full Text] [Related]
19. The role of CDK4/6 inhibitors in early breast cancer. Gil-Gil M; Alba E; Gavilá J; de la Haba-Rodríguez J; Ciruelos E; Tolosa P; Candini D; Llombart-Cussac A Breast; 2021 Aug; 58():160-169. PubMed ID: 34087775 [TBL] [Abstract][Full Text] [Related]
20. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib. Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]